Biomarkers · Cardiometabolic

Lipid Accumulation Product (LAP)

Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).

LAP and risk of death

Published curve higher than the NHANES fitNHANES fit higher

Risk of death relative to the curve's reference value, drawn from the published study (source below).

Published risk of death4.28×third vs first LAP tertile (normal weight postmenopausal women; P < 0.001) (95% CI 1.94–9.44) · Normal-weight subset of 875 postmenopausal women (cohort of 2,279 men and 875 women referred to coronary angiography); no significant association in men

LAP by age and sex

Each bar runs from the 5th to the 95th percentile, the darker part from the 25th to the 75th, and the tick is the median. Not a reference range or a target.

The percentiles as a table

Each row is one sex and age band: the values below which 5%, 25%, 50%, 75% and 95% of people fall (cm x mmol/L), from the survey named in the row. Not a reference range or a target.
Sex	Age	5th	25th	Median	75th	95th	n	Cycle / source
All	20-39	6.54	14.3	29.5	56.4	130	672	NHANES 2017-2018
All	40-59	8.89	22.8	42.3	77.9	153	729	NHANES 2017-2018
All	60+	14.3	29.0	46.8	71.7	124	852	NHANES 2017-2018
All	all	7.67	20.5	38.8	69.7	134	2,253	NHANES 2017-2018
Men	20-39	5.68	14.5	28.9	51.8	131	310	NHANES 2017-2018
Men	40-59	10.7	26.4	43.9	81.1	153	351	NHANES 2017-2018
Men	60+	13.9	30.8	53.1	74.5	125	437	NHANES 2017-2018
Men	all	7.60	20.5	39.6	71.3	138	1,098	NHANES 2017-2018
Women	20-39	6.73	13.9	29.7	59.2	127	362	NHANES 2017-2018
Women	40-59	7.87	20.7	40.9	76.1	157	378	NHANES 2017-2018
Women	60+	15.2	26.7	44.7	67.9	119	415	NHANES 2017-2018
Women	all	7.72	20.6	37.4	67.5	130	1,155	NHANES 2017-2018

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Diseases and conditions

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↑ Non-alcoholic fatty liver disease · subjects with vs without NAFLD	+34.9 cm x mmol/L (95% CI 30.59 to 39.31)	NAFLD vs no NAFLD · 16 observational studies (mostly cross-sectional)	meta analysis · PMID 36922815
↑ Obstructive sleep apnea · OSA / high risk for OSA vs controls / low risk	SMD +0.53 (95% CI 0.25 to 0.81)	OSA or high OSA risk vs controls or low risk · 14 studies (5 for LAP)	meta analysis · PMID 37386562
↑ Polycystic ovary syndrome · women with PCOS vs healthy controls (pooled LAP 37.1 vs 23.9)	SMD +0.597 (95% CI 0.469 to 0.726)	PCOS vs healthy controls · Women with PCOS vs controls, 32 studies for LAP	meta analysis · PMID 41057845

Sources

Risk curve: Wehr E 2011 (PMID 21394091): all-cause HR 4.28 (1.94-9.44) third vs first LAP tertile (normal weight postmenopausal women; P < 0.001). Scaled to US values (NHANES).
Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-Pietsch B. The lipid accumulation product is associated with increased mortality in normal weight postmenopausal women. Obesity (Silver Spring). 2011;19(9):1873-1880.

Map Lipid Accumulation Product (LAP) against another biomarker.

Map LAP against another marker